Merkel Cell Carcinoma Overview

Save information for later
Sign Up

Learn About Merkel Cell Carcinoma

What is the definition of Merkel Cell Carcinoma?
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer. It usually develops as a single, painless, bump on sun-exposed skin. The bump may be skin-colored or red-violet, and tends to grow rapidly over weeks to months. It may spread quickly to surrounding tissues, nearby lymph nodes, or more distant parts of the body. Factors associated with developing MCC include increasing age, fair skin, a history of extensive sun exposure, chronic immune suppression, and the Merkel cell polyomavirus. The Merkel cell polyomavirus has been detected in most people who have MCC.
What are the alternative names for Merkel Cell Carcinoma?
  • Merkel cell carcinoma
  • Carcinoma, merkel cell
  • Cutaneous neuroendocrine carcinoma
  • Merkel cell cancer
  • Merkle tumors
Who are the top Merkel Cell Carcinoma Local Doctors?
Vernon K. Sondak
Elite in Merkel Cell Carcinoma
Dr. Vernon K. Sondak
General Surgery
Elite in Merkel Cell Carcinoma
Dr. Vernon K. Sondak
General Surgery

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vernon Sondak is a General Surgeon in Tampa, Florida. Dr. Sondak is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Neuroendocrine Tumor, Adult Soft Tissue Sarcoma, and Lymphadenectomy. Dr. Sondak is currently accepting new patients.

Guilherme Rabinowits
Elite in Merkel Cell Carcinoma
Dr. Guilherme Rabinowits
Oncology | Hematology Oncology | Hematology
Elite in Merkel Cell Carcinoma
Dr. Guilherme Rabinowits
Oncology | Hematology Oncology | Hematology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
888-860-2778
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Guilherme Rabinowits is an Oncologist and a Hematologist Oncology provider in Tampa, Florida. Dr. Rabinowits is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Merkel Cell Carcinoma, Tongue Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Neuroendocrine Tumor. Dr. Rabinowits is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Merkel Cell Carcinoma
Dr. Jeffrey M. Farma
General Surgery
Elite in Merkel Cell Carcinoma
Dr. Jeffrey M. Farma
General Surgery

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
215-707-3326
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Farma is a General Surgeon in Philadelphia, Pennsylvania. Dr. Farma is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Merkel Cell Carcinoma, Gastrostomy, and Lymphadenectomy.

View All Doctors
What are the latest Merkel Cell Carcinoma Clinical Trials?
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Subjects With Advanced Or Metastatic Merkel Cell Carcinoma
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Subjects With Advanced Or Metastatic Merkel Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint-Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint-Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via intralesional injection in a single lesion...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center